Fig. 3From: Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritisForest plot showing the difference from placebo with namilumab for DAS28-CRP mean change from baseline. CI confidence interval, CRP C-reactive protein, DAS disease activity scoreBack to article page